Industrial biotechnology for improved manufacture of medicinal alkaloids

用于改进药用生物碱生产的工业生物技术

• 批准号: LP160100182
• 负责人: Prof Sally Gras
• 金额: $ 21.19万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-11-23 至 2019-11-22
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP160100182
• 关键词: Industrial; biotechnology; improved; manufacture; medicinal

Industrial biotechnology for improved manufacture of medicinal alkaloids. This project aims to develop a new semi-synthetic route for the manufacture of Codeine from Thebaine. Codeine is manufactured by the chemical conversion of poppy-derived Morphine, which is low yielding and environmentally unfriendly. This project will investigate and optimise two key enzymes in the biosynthetic pathway to Codeine and develop an innovative bioreactor to achieve high yield. It will research industrial biotransformations, providing a greener and cheaper process for increased global access to Codeine. Australian opiate manufacturing is expected to benefit from value adding and increased flexibility introduced by a biotechnology approach.

改善药用生物碱生产的工业生物技术。本项目旨在开发一种从底拜因生产可待因的新半合成路线。可待因是由罂粟衍生的吗啡化学转化而成的，产量低，对环境不友好。该项目将研究和优化可待因生物合成途径中的两种关键酶，并开发一种创新的生物反应器以实现高产量。它将研究工业生物转化，为增加可待因的全球获取提供一种更环保、更便宜的过程。预计澳大利亚的鸦片制剂制造业将受益于生物技术方法带来的增值和更大的灵活性。